ShareValue scores for GMT.WAR: Valuation 38, Quality 43, Growth 54, Health 50.
GMT.WARGPW
Genomtec S.A.
PLN 4.14
(-3.39%)
GMT.WARGPW
Genomtec S.A.
Verdicts
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
Rating
Trap Risk
Return
Company Details
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was incorporated in 2008 and is based in Wroclaw, Poland.